Exponent/$EXPO

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Exponent

Exponent Inc is a science and engineering consulting firm that provides solutions to complex problems. The company's consultant team is composed of scientists, physicians, engineers, as well as business and regulatory consultants. The company currently operates through two segments. The engineering and other scientific segments, which account for the majority of revenue, provide servicing encompassing biomechanics, biomedical engineering, buildings and structures, civil engineering, construction consulting, etc. The environmental and health segment covers chemical regulation and food safety, ecological and biological sciences, environmental and earth sciences and others. The company generates almost all of its revenues from America.

Ticker

$EXPO
Primary listing

Industry

Professional Services

Employees

966

ISIN

US30214U1025

Exponent Metrics

BasicAdvanced
$3.8B
36.35
$2.04
0.96
$1.16
1.62%

What the Analysts think about Exponent

Analyst ratings (Buy, Hold, Sell) for Exponent stock.

Bulls say / Bears say

Exponent Inc. reported quarterly adjusted earnings of 46 cents per share for the quarter ended December 31, 2024, surpassing analyst expectations of 40 cents, indicating strong financial performance. (reuters.com)
The company raised its revenue and margin expectations for the year, reflecting confidence in its strategic initiatives and market position. (investing.com)
Exponent is focusing on strategic recruitment and development for growth and profitability, with AI-related projects, particularly in advanced driver assistance and medical devices, gaining increased relevance. (investing.com)
The company's CFO, Richard L. Schlenker Jr., sold approximately $4.3 million worth of company shares, which could be perceived as a lack of confidence in the company's future performance. (investing.com)
Exponent's environmental and health segment experienced a 3% revenue decrease in the fourth quarter, impacted by client budget constraints leading to delays in litigation work. (exponent.com)
The company anticipates revenues before reimbursements to be flat to down modestly in 2024, indicating potential challenges in maintaining growth momentum. (exponent.com)
Data summarised monthly by Lightyear AI. Last updated on 6 Jun 2025.

Exponent Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Exponent Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $EXPO

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs